Range
- - -
Vol / Avg.
-/291.4K
Div / Yield
-
52 Wk
24.78 - 55.22
Mkt Cap
1.5B
Payout Ratio
-
Open
-
P/E
-
EPS
0.8
Shares
43.6M
Outstanding
43.6M
Total Float
34.6M
Benzinga - 20 hours ago
Benzinga - Jun 4, 2021, 9:09AM
Benzinga - Jun 4, 2021, 9:04AM
Benzinga - May 19, 2021, 4:03PM
Benzinga - May 7, 2021, 1:05PM
Benzinga - May 6, 2021, 4:47PM
Benzinga - Apr 29, 2021, 9:03AM
Benzinga - Apr 27, 2021, 4:01PM
Benzinga - Apr 20, 2021, 12:18PM
Benzinga - Apr 20, 2021, 9:19AM
Benzinga - Apr 12, 2021, 9:07AM
Benzinga - Mar 22, 2021, 11:35AM
Benzinga - Mar 12, 2021, 10:08AM
Benzinga - Mar 1, 2021, 7:02AM
Benzinga - Feb 25, 2021, 4:16PM
Benzinga - Feb 18, 2021, 7:23AM
Benzinga - Feb 16, 2021, 4:04PM
Benzinga - Feb 12, 2021, 4:03PM
Benzinga - Jan 15, 2021, 10:26AM
Benzinga - Jan 15, 2021, 8:24AM
Benzinga - Dec 18, 2020, 9:07AM
Benzinga - Dec 18, 2020, 9:06AM
Benzinga - Dec 16, 2020, 9:03AM
load more
Sector: Health Care.Industry: Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-05
REV
Q1 2021Est.ActualSurprise
EPS0.1900.750 0.5600
REV44.470M5.383M-39.087M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
YMABY-mAbs Therapeutics0%1.5B

Y-mAbs Therapeutics Frequently Asked Questions

Q

How do I buy Y-mAbs Therapeutics (YMAB) stock?

A

You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Y-mAbs Therapeutics's (YMAB) competitors?

A

Other companies in Y-mAbs Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Precigen (NASDAQ:PGEN), Cerevel Therapeutics Hldg (NASDAQ:CERE), Arcutis Biotherapeutics (NASDAQ:ARQT) and Sangamo Therapeutics (NASDAQ:SGMO).

Q

What is the target price for Y-mAbs Therapeutics (YMAB) stock?

A

The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by JP Morgan on March 22, 2021. The analyst firm set a price target for 52.00 expecting YMAB to rise to within 12 months (a possible 52.00% upside). 6 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Y-mAbs Therapeutics (YMAB)?

A

The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $34.21 last updated Wed Jun 23 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Y-mAbs Therapeutics (YMAB) pay a dividend?

A

There are no upcoming dividends for Y-mAbs Therapeutics.

Q

When is Y-mAbs Therapeutics (NASDAQ:YMAB) reporting earnings?

A
Y-mAbs Therapeutics’s Q2 earnings are confirmed for after-market on August 5, 2021.
Q

Is Y-mAbs Therapeutics (YMAB) going to split?

A

There is no upcoming split for Y-mAbs Therapeutics.

Q

What sector and industry does Y-mAbs Therapeutics (YMAB) operate in?

A

Y-mAbs Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.